The Effective Statistician - in association with PSI

The Effective Statistician - in association with PSI

The Effective Statistician - in association with PSI

The benefit-risk tolerability measure - a new way to reach insights into benefit-risk and more

Download it: MP3 | AAC | OGG | OPUS

As part of his master thesis, he worked on an idea; I had sketched out a couple of years ago but never had the time to fully think through. I wanted to explore how we could utilize existing study data to inform the benefit-risk assessment of different therapies. In this episode, you will learn a new concept which also is related to minimal clinical meaningful differences and helps to assess the impact of various adverse events on the patient. Specifically, we dive into:

  • What is the benefit-risk tolerability measure?
  • How can we use the information on which patient discontinue to inform the benefit-risk assessment?
  • How does the model help us rank adverse events in order of their importance?
  • Which adverse events cannot be classified with the model?
  • How to use the model to inform relevant difference for efficacy endpoints?

Listen to this episode and share it with your friends and colleagues!


Comments


New comment

By submitting your comment you agree that the content of the field "Name or nickname" will be stored and shown publicly next to your comment. Using your real name is optional.

About this podcast

The podcast from statisticians for statisticians to have a bigger impact at work. This podcast is set up in association with PSI - Promoting Statistical Insight. This podcast helps you to grow your leadership skills, learn about ongoing discussions in the scientific community, build you knowledge about the health sector and be more efficient at work. This podcast helps statisticians at all levels with and without management experience. It is targeted towards the health, but lots of topics will be important for the wider data scientists community.

by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry

Subscribe

translation missing: en.themes.custom.follow_us